Accueil » La R&D d'Unicancer » Les publications de la R&D d'Unicancer » Les publications

Publications de la R&D d'Unicancer

2016

Mutational profile of metastatic breast cancers: a retrospective analysis

Lefebvre C et al., PLoS Med. 2016 Dec 27;13(12)

2016

What specifications for a centre or network of excellence in clinical research ?

Diebolt V et al., Thérapie (2016) 71, 51-57

2016

Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.

Piperno-Neumann S et al., Lancet Oncol. 2016 Aug;17(8):1070-80.

2016

The ENCCA-WP7 /EuroSarc /EEC /PROVABES /EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report

Kager L et al., Clin Sarcoma Res. 2016 Mar 16;6:3.

2016

Factors associated with patient-reported cosmetic outcome in the Young Boost Breast Trial

P. J.A.M. Brouwers et al., Radiother Oncol. 2016 Jul;120(1):107-13.

2016

Breast cancer screening: On our way to the future [article in French]

Delaloge S et al., Bull Cancer. 2016 Jul 26.

2016

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Cardoso F et al., N Engl J Med. 2016 Aug 25;375(8):717-29.

2016

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Bonnefoi H et al., Annals of Oncology 0: 1–6, 2016

2016

A Systematic Evaluation of Blood Serum and Plasma Pre-Analytics for Metabolomics Cohort Studies

Jobard E et al., Int. J. Mol. Sci. 2016, 17, 2035

2016

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

Bertucci F et al., Lancet Oncol. 2016 May;17(5):600-11